Drugs / Sinovac EV71 vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03909074 | Mar → Jun 2019 | hand, foot and mouth disease | Sinovac Biotech Co., Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sinovac EV71 vaccine | “Non-inferiority and superiority analyses were made to determine the immunogenicity of Sinovac EV71 vaccine in older children (Older-S group), comparing with that of control...” PMID 33269798 ↗ Apr 2021 |
| Modality | Vaccine | “The Sinovac enterovirus 71 (EV71) vaccine has been given to children aged 6-35 months with good safety, immunogenicity, and efficacy.” PMID 33269798 ↗ Apr 2021 |